Bromocriptine (1.25 mg BID) was administered orally to a 23 year old asymptomatic female with accelerated growth and a parasellar tumor (tissue type unknown). Other forms of therapy were refused. Length increased from 76 to 95 cm (22 cm/yr) and weight increased from 10 to 16.25 kg between ages 13 and 23 months. Bone age was 2 years at a chronolorical age of 18 months. Somatomedin C level was 4.3 Ulml (n=2: normal 0.8 to 2.2 Ulml). Thirteen growth hormone values during overnight monitoring averaged 4.7 ng/ml, range 1.8 to 7.9 ng/ml. Suppression to 5.0 nglml was seen during an OGTT. Other neuroendocrine functions were normal. No evidence of isosexual precocity was noted. Somatomedin C levels were 3.2, 2.6, 2.5. 2.4, and 2.2 U/ml on days 1 to 5 of therapy, 2.5 Ulml at 14 days and 2.7 Ulml at 56 days. Length increased from 95 to 97 cm (4.8 cm/ yr) during the first 5 months of therapv. CT scan at 5 months shows no change in tumor size. The patient remains asymptomatic.
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The decrease in levels of somatomedin C associated with a reduction in the growth rate may have resulted from decreased GH oroduction; however. other effects of bromocriptine, such as blockinr the peripheral action of somatomedins may be involved. In rats permanent stunting follows neonatal head-irradiation (Head-X); during the post-weaning period full catch-up growth (CU) occurs after fasting (F); failure of CU occurs after cortisone treatment (C); and superimposition of F or C on Head-X results in similar responses in the stunting after Head-X. In this study growth hormone (GH) secretory profiles were determined in rats treated with Head-X, F or C. Superior vena cava blood was sampled at 15 min intervals during the light phase in chronically cannulated undisturbed animals. Sampling duration was 9 h in Head-X, 6 h in F, and 12 h in C. The results, expressed as area units115 min under the curve of plasma GH con- 
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COKTROLS
(13) 98.4t11.9 (16) 84.6~10.9 (7) 55.3C7.4 P <0.025 ~'3.05 ~0.025 Normal pulsatile GH rhythm existed in all three models. The data indicate that GH controls are linked to the CU control. That GH secretion is decreased in Head-X is conpatible with the concept that brain injury has reset growth controls for a smaller body size. We conclude that CH release is linked to the putative CU control through a mechanism which senses the discrepancy between actual body size and normal body size for age.
Stephen Greene, Toni Torresani, Andrea Prader (yr) was similar (Group I 12.4 '3.4; Group I1 13.6 f2.0; Group I11 13.4 '3.01, mean ( ' S D ) bone age (BA, yr) however was delayed in Group I (10.4 i3.7) compared with Group II(14.1 11.3) and Group 1 1 1 (13.4 '3.1) p <0.0005. Results are expressed as mean %EM. Pre-ex. GH was similar (Group I 6.5 '1.9; Group I1 8.9 f2.6; Group I11 9.0 i2.5). In contrast post-ex. GH was higher in tall (36.6 '5.5) compared with short (16.6 '3.1) and normal children (21.2 '3.5), p 40.005. However, combining the three groups revealed a high post-ex. GH in relation to the pubertal growth spurt independent of height; GH at BA <I0 yrs 13.1 f3.0; BA >10 yrs 25.5 f2.8, p<0.005: GH at P3P4, 34.7 t4.5; at PIP2 15.2 '2.4 and at P5 20.7 +6.3, p <0.0005). Raised post exercise GH in tall children appears to reflect a normal change in secretion of GH at puberty and this change 1s also present in short children. Evidently, puberty induces a rapid increase of spontaneous hGHsecretion. 2) In 48 children (P 1) with pituitary dwarfism total hGH secretion was 934 2 468 ng. 3) In 123 children with constitul tional delay of growth and adolescence, total secretion in P 1, P 2 and P 314 was reduced by 43; 43; 67 %, resp., compared to controls. Differences were statist. highly significant. Hence, constitutional delay is caused by decreased spontaneous hGH secretion. 4) 6 of 10 children with IUGR showed values within (i t 2 S), 4 values < (i -2 S). IUGR is apparently no uniform disorder. 5) In 24 girls with Turner's syndrome, (x S) was 2018 ? 1240 ng. In 17 girls total secretion was <(i -2 S) of the control group. 6) 3 girls with chronic inflammatory diseases under prednisone therapy had a total hGH secretion of 280; 595; 673 ng. Cessation of treatment caused normalization. Evidently corticoids strongly suppress spontaneous hGH-secretion. 7) In 9 children with severe obesity, 5 of them with Prader-Willi-syndrome, total hGH-secretion was 532 2 275 ng -with no differences between simple obesity and PWS. Low hGH-secretion in PWS is rather due to excessive obesity than to impaired growth. 
.
A
Ten children with documented Growth Hormone Deficiencyhadtheirb~dy composition determined before and during Human Growth Hormone treatment. Body composition was determined by underwater welghing and selected measures of subcutaneous fat thickness. The measurements were obtained before the onset of Human Growth Hormone therapy and subsequently every 6 months during the treatment.
During the first 6 months of treatment, most patient's demonstrated an increase in body fat without significant increase in lean body mass. During the second 6 months and subsequent periods of treatment, a decrease in body fat and increase in lean body mass was observed in most of the patients.
These data tend to indicate that for children receiving Human Growth Hormone therapy changes in body composition are not uniform. Body fat appears to increase in the first 6 months and lean body mass increases during subsequent periods of treatment.
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A recently described method to investigate kGH receptors on circulating human blood cells has been used to study xhe effect of trypsin and antitrypsin on hormone binding to mononuclear cells. Trypsinization of cells lead to a considerable decrease of specific binding and of binding affinity (affin'ty onstant after o rntnutes trypsiniration 0.5~10' KF versus 1.5~10' M-in untreated control cells). Zxposure of peripheral mononuclear cells to antitrypsin activities-was followed by a steady increase of affinity and sp cif'c binding (affinity cgnstynts: with 10 KIJ I .9x105 iTIt, with 100 XIU 2 . 4~1 0 ) I -, with 1300 Xi3 3 . 6~1 0~ M ) . "is antitrypsin effect exceeds the binding values expected arter blocking try3sin activitiss in the incubation medium. In a subset of experiments somatomedic-3 was used as the antitrypsin moiety and was shown to increase spec-fic G 3 Slnding in a similar manner as did ant'tr sin (,vith 1300 ng SM-5 affinity constant 12.0~10 4 p, ,,eciTic c.n binding 9.7 ' $ of total radioactivity). It is conclud?d that enzymatic factors and their inhibitors including partially GH dependent noieties i.ike somatomedin-B modu.-late 39-induced action by rezulnting specific 3B receptors in CB target tissues.
